Targets › CHIT1
1 program from 1 company in 1 trial: 1 Phase 2; Immunology; next expected readout Aug 2027.
Degrades chitin, chitotriose and chitobiose. May participate in the defense against nematodes and other pathogens. (UniProt, Q13231)
Open in Phaseline: the race on CHIT1, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Molecure | OATD-01 Chitinase-1 (CHIT1) inhibitor | CHIT1 | Phase 2 | Pulmonary Sarcoidosis | Aug 2027 |
Pulmonary Sarcoidosis (1)
small molecule (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.